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Abstract
Introduction
Although several studies have explored factors associated with loss to follow-up (LTFU)
from HIV care, there remains a gap in understanding how these factors vary by setting, vol-
ume of patient and patients’ demographic and clinical characteristics. We determined rates
and factors associated with LTFU in HIV care Lilongwe, Malawi.
Methods
We conducted a retrospective cohort study of HIV-infected individuals aged 15 years or
older at the time of registration for HIV care in 12 ART facilities, between April 2012 and
March 2013. HIV-positive individuals who had not started ART (pre-ART patients) were clini-
cally assessed to determine ART eligibility at registration and during clinic follow-up visits.
ART-eligible patients were initiated on triple antiretroviral combination. Study data were
abstracted from patients’ cards, facility ART registers or electronic medical record system
from the date of registration for HIV care to a maximum follow-up period of 24 months.
Descriptive statistics were undertaken to summarize characteristics of the study patients.
Separate univariable and multivariable poisson regression models were used to explore fac-
tors associated with LTFU in pre-ART and ART care.
Results
A total of 10,812 HIV-infected individuals registered for HIV care. Of these patients, 1,907
(18%) and 8,905 (82%) enrolled in pre-ART and ART care, respectively. Of the 1,907 pre-
ART patients, 490 (26%) subsequently initiated ART and were included in both the pre-ART
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and ART analyses. The LTFU rates among patients in pre-ART and ART care were 48 and
26 per 100 person-years, respectively. Of the 9,105 ART patients with reasons for starting
ART, 2,451 (27%) were initiated on ART because of pregnancy or breastfeeding (Option B+)
status. Multivariable analysis showed that being35 years and female were associated with
decreased risk of LTFU in the pre-ART and ART phases of HIV care. However, being in
WHO clinical stage 3 (adjusted risk ratio (aRR) 1.35, 95% confidence interval (CI): 1.20–
1.51) and stage 4 (aRR 1.87, 95% CI: 1.62–2.18), body mass index 18.4 (aRR 1.24, 95%
CI: 1.11–1.39) at ART initiation, poor adherence to clinic appointments (aRR 4.55, 95% CI:
4.16–4.97) and receiving HIV care in rural facilities (aRR 2.32, 95% CI: 1.94–2.87) were
associated with increased risk of LTFU among ART patients. Being re-initiated on ART once
(aRR 0.20, 95% CI: 0.17–0.22), more than once (aRR 0.06, 95% CI: 0.05–0.07), and being
enrolled at a low-volume facility (aRR 0.25, 95% CI: 0.20–0.30) were associated with
decreased risk of LTFU from ART care.
Conclusion
A sizeable proportion of ART LTFU occurred among women enrolled during pregnancy or
breast-feeding. Non- compliance to clinic and receiving ART in a rural facility or high-volume
facility were associated with increased risk of LTFU from ART care. Developing effective
interventions that target high-risk subgroups and contexts may help reduce LTFU from HIV
care.
Introduction
Increased access to antiretroviral therapy (ART) in resource-limited settings is an unprece-
dented success story for HIV programs. As of June 2015, 15.8 million people received ART
globally, the majority, 10.7 million in sub-Saharan Africa (SSA)[1], a tremendous increase
from just over 0.8 million people in 2005 [2]. However, these successes are being challenged by
high rates of loss to follow-up (LTFU) [3].
LTFU from HIV care is a major public health concern. LTFU increases the risk of drug
resistance and treatment failure in cases where death is not the reason for LTFU. Previous
studies showed that patients with treatment interruptions are more likely to develop treatment
failure [4,5], viral rebound, and clinically significant drug resistance [4]. At the national pro-
gram and clinic levels, not accounting for LTFU may bias retention estimates and misdirect
resources when planning and budgeting for HIV care [6].
Factors and reasons for LTFU at patient and system levels include advanced HIV disease,
older age, male gender, longer distance to clinics in patients not on ART, unregistered trans-
fers out and undocumented deaths in patients on ART [6–9]. Factors associated with LTFU
remain complex. Comparing facility characteristics in urban and rural HIV with varying
patient volumes may inform the design of intervention that optimize retention.
Effective early patient tracing may reduce LTFU and improve retention. However, tracing
all patients who have missed appointments and those LTFU can be resource and time-inten-
sive. As such, the Malawi guidelines recommend prioritizing tracing patients that miss ART
appointment or those eligible for ART [10]. Despite this guidance, implementation is chal-
lenged by health systems constraints including chronic human resource shortages and limited
health infrastructure; as a result, facility- and community-level interventions to improve reten-
tion differs widely across the country.
Loss to follow-up in antiretroviral program
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Optimizing retention by mitigating the varying risk factors for LTFU may greatly impact
Malawi’s trajectory towards epidemic control. Retention interventions may be optimised in
terms of person, place, and time by identifying individual-level or context specific risk factors
that may predispose a patient to be LTFU. This paper describes LTFU and associated factors in
pre-ART and ART patients at 12 ART facilities, prior to the implementation of a quality
improvement (QI) collaborative aimed at optimizing retention in care in Lilongwe district,
Malawi.
Methods
Setting
Data used for this study was obtained from five rural and seven urban ART facilities in
Lilongwe District, Malawi. All six high-volume ART facilities, with more than 400 new ART
patients per year, used an electronic medical records system (EMRs) for patient management
and the remaining low-volume facilities used paper-based systems. Five high-volume facilities
were located in urban setting while one high-volume facility was in rural setting. HIV-infected
adults were registered for HIV care in the EMRs or paper patient cards. During the observa-
tion period, ART eligibility was defined in accordance with the national guidelines: World
Health organisation (WHO) clinical stage 3 or 4 or having a CD4 count of 350 cells/μl. Preg-
nant and breastfeeding women were also considered eligible irrespective of their CD4 count or
WHO clinical stage as Malawi had adopted Option B+ for prevention of mother-to-child
transmission (PMTCT) of HIV. Pre-ART patients, HIV-positive individuals who had not
started ART (pre-ART patients), were clinically assessed based on WHO clinical criteria every
2 months to determine ART eligibility. For those not eligible based on WHO clinical stage,
CD4 was repeated every 6 months when feasible. Therefore, CD4 data were generally available
for patients in WHO stage 1 or 2. At each visit, pre-ART and ART patients received co-trimox-
azole as prophylaxis to prevent opportunistic infections. ART-eligible patients were initiated
on triple antiretroviral (ARV) combination: Tenofovir, Lamivudine, and Efavirenz and routine
follow-up visits were scheduled monthly or every two months. Based on the data collection
system, subsequent ART clinic appointments were either calculated manually or electronically
based on the ARV regimen and prescribed schedule, number of tablets dispensed, and the
number of tablets remaining from the previous dispensing visit. ART programme outcomes
(alive and on ART, stopped ART, or transferred-out) were updated on the patient card or in
EMRs at each clinic visit or retrospectively. Stopping ART, transferring care or death were also
updated retrospectively in facilities with patient tracing systems.
Study design and population
This retrospective cohort study used routine clinic data collected from HIV-infected individu-
als who were 15 years of age or older at the time of registration for HIV care in the ART facili-
ties, between April 2012 and March 2013.
Variable definitions
Pre-ART patients comprised of two categories of patients relative to ART; patients who were
not eligible for ART at baseline and those eligible but never started ART for at least three
months despite attending clinic consultations. The primary outcome variable was LTFU
defined as failure to come to the clinic for at least 60 days from the patient’s appointment date.
Patients were classified as (i) “stopped treatment” when they stopped ART during the follow-
up period including medical reasons; (ii) “transferred-out” if the patient had a formally
Loss to follow-up in antiretroviral program
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recorded transfer to another clinic, (iii) “dead” if the patient died from any cause. Other vari-
ables of interest were adherence to clinic appointments and ART re-initiation. Adherence to
clinic appointments was defined as having at least 80% of the ART visits before 7 days after a
scheduled appointment. Re-initiation was defined as restarting ART treatment after stopping
ART for at least 60 days.
Data collection and statistical analysis
Data were abstracted from individual patient cards, facility ART registers or EMRs from the
date a patient registered at an HIV facility up to a maximum follow-up period of 24 months.
Patients who initially registered for pre-ART services and later started ART had their data
abstracted for pre-ART and for ART follow-up periods. A time-to-event analysis was con-
ducted for pre-ART and ART times, separately. For person-time calculation, the analysis
period began when patients enrolled in pre-ART care or initiated ART at the facility. Observa-
tion of ‘time at risk’ for LTFU during pre-ART care ended either at the time of an outcome
(started ART, LTFU, transfer-out, or death) or at 24 months after pre-ART registration. For
ART patients, observation of ‘time at risk’ of LTFU ended either at the time of an outcome
(stopped ART, LTFU, transferred-out, or death) or at 24 months after ART registration. Sepa-
rate Poisson regression models were used to explore factors associated with LTFU in pre-ART
and ART care. A null hypothesis of no within-facility clustering, versus the alternative of some
within-facility clustering were tested (p = 0.065). All the analysis did not account for clustering
at facility level because within facility variability was not significant. The models were adjusted
for age and sex, a priori. Model results were shown as risk ratios (RR) and adjusted RR (aRR)
with 95% confidence intervals (CI).
Ethics approval
The study was approved by the Malawi National Health Science Research Committee in
Lilongwe, Malawi and by the office of the Associate Director for Science of the U.S. Centers
for Disease Control and Prevention in Atlanta, Georgia.
Results
A total of 10,812 HIV-positive individuals were enrolled into HIV care at the 12 facilities
between April 2012 and March 2013; of these patients, 1,907 (18%) registered for pre-ART
care and 8,905 (82%) for ART care. Of the 1,907 pre-ART patients, 490 (26%) subsequently
started ART and were included in both the pre-ART and ART analyses, resulting in a total of
9397 ART patients. The majority of patients were enrolled in six high-volume facilities; 1,681
(88%) of pre-ART patients and 8,390 (89%) of ART patients. On average, low-volume facilities
enrolled 170 (range 99−221) patients per year while large volume facilities enrolled 1330
(range 403−4133) patients per year. There were no significant differences in demographic
characteristics between patients enrolled at low and high volume facilities.
Pre-ART patients
Among the pre-ART patients, 1,098 (58%) were female (Table 1). Median age at enrolment in
pre-ART care was 31 years (interquartile range (IQR): 26−38). Median CD4 count was 409
cells/μl (IQR: 290–555); men had lower median CD4 counts compared to women (374 vs 441
cells/μl, p<0.001).
Loss to follow-up in antiretroviral program
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ART patients
Of the 9,397 ART patients, 6,213 (66%) were female (Table 1). Median age at ART initiation
was 32 years (IQR: 27−38) and the majority (45%) of patients were aged 25−34 years. Among
those with documented WHO clinical stage, 50% had WHO stage 3 or 4 conditions. Among
ART patients with documented CD4 counts, women had higher median CD4 counts at ART
initiation than men, 241 cells/μl and 186 cells/μl, respectively. Of all patients who initiated
ART, 2,451 (26%) were pregnant or breastfeeding and started on ART for PMTCT and 8,380
(89%) were enrolled at high-volume facilities.
Pre-ART and ART program outcomes by facility size
Median follow-up time for the 1,907 pre-ART patients was 8.5 (2.4−23) months. Overall rate
of LTFU was 48 (95% CI, 45−52) per 100 person-years. Low-volume facilities did not docu-
ment any LTFU patients at 12 or 24 months of follow-up (Table 2). In contrast, among 1,681
pre-ART patients enrolled for HIV care at high-volume facilities, 47% were LTFU after 12
months of follow-up; at 24 months, 54% patients were LTFU. There were no patients reported
Table 1. Baseline characteristics of HIV-infected persons who registered for pre-ART and ART care between April 2012 and March 2013 in Lilongwe, Malawi.
Characteristics Pre-ART ART
Total Low-volume load
facilities
(n = 226)
High-volume load
facilities 
(n = 1681)
Total Low-volume load
facilities
(n = 1107)
High-volume load
facilities
(n = 8380)
Gender
Male 809 (42%) 97 43% 712 42% 3162 (34%) 343 34% 2819 34%
Female 1098 (58%) 129 57% 969 58% 6213 (66%) 653 66% 5560 66%
Unknown 22 (<1%) 21 2% 1 <1%
Age
15–24 361 (19%) 27 12% 334 20% 1582 (17%) 117 12% 1465 17%
25–34 865 (45%) 97 43% 768 46% 4189 (45%) 407 43% 3782 45%
35–44 457(24%) 64 29% 393 23% 2426 (26%) 275 29% 2151 26%
45 220 (12%) 35 16% 185 11% 1131 (12%) 150 16% 981 12%
Unknown 4 (<1%) 3 1% 1 <1% 69 (<1%) 68 7% 1 <1%
BMI category
<18.5 157 (9%) 17 13% 140 9% 1356 (15%) 129 19% 1227 15%
18.5–24.9 1238 (70%) 95 70% 1143 70% 5689 (64%) 423 62% 5266 64%
25.0 367 (21%) 24 18% 343 21% 1819 (21%) 135 20% 1684 21%
Unknown 145 (8%) 90 3% 55 40% 533 (6%) 330 32% 203 2%
CD4 cell count at registration
<350 376 (34%) 17 15% 359 37% 2375 (92%) 242 92% 2133 92%
350–500 363 (33%) 48 42% 315 32% 175 (7%) 11 4% 164 7%
>500 354 (32%) 50 43% 304 31% 32 (1%) 9 3% 23 1%
Unknown 814 (43%) 111 49% 703 42% 6815 (73%) 755 74% 6060 72%
WHO clinical stage
1 or 2 1352 (83%) 101 81% 1251 83% 3927 (50%) 561 59% 3366 48%
3 222 (14%) 23 19% 199 13% 3149 (40%) 302 32% 2847 41%
4 61 (3%) 0 0% 61 4% 828 (10%) 95 10% 733 11%
Unknown 272 (14%) 102 45% 170 10% 1493 (16%) 59 6% 1434 17%
High-volume load facilities enrolled at least 400 ART patients per year
BMI: body mass index; ART: antiretroviral therapy, unknown category is excluded in the percentage calculations
https://doi.org/10.1371/journal.pone.0188488.t001
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as transferred-out or dead both at 12 and 24 months of follow-up in pre-ART care at high-vol-
ume facilities.
Of the 9,397 ART patients, 49 had missing outcomes and 9,348 ART patients contributed
11,527 person-years. The overall rate of LTFU in ART patients was 26 (95% CI 25–27) per 100
person-years and the median follow-up was 20.9 (IQR 3–23) months. ART outcomes were not
documented in 49 patients: 40 enrolled in low-volume facilities and 9 in high-volume facilities.
At 12 months post-ART initiation, more patients were reported to be alive and on ART in
low-volume facilities than in high-volume facilities (p<0.001) and the difference was still sig-
nificant at 24 months (Table 2).
Factors associated with loss to follow-up from pre-ART and ART care
In univariable analysis of pre-ART patients, having a body mass index (BMI) < 18.4, baseline
WHO stage 3 and stage 4 were associated with an increased risk of LTFU (Table 3). Being
female, age 35−44 years, or age45 years and having a baseline CD4 count of>350 cells/μl
were associated with a decreased risk of LTFU. These factors remained significantly associated
with LTFU after adjusting for potential confounders in the multivariable analysis.
In univariable analysis of ART patients, being female, younger age 15−24 years, BMI<18.5,
baseline WHO stages 3 and 4 were associated with increased risk of LTFU (Table 4). Women
who started ART based on Option B+ criteria had a higher risk of LTFU than patients who
started ART based on CD4 count. The risk of LTFU was higher among patients who were not
adherent to scheduled clinic appointments compared to those who were adherent. Predictors
of decreased risk of LTFU included age 35years and above, being re-initiated on ART once,
being enrolled at a low-volume facility and receiving care from an urban facility.
Table 2. ART program outcomes by time in HIV care among HIV-infected persons who registered for pre-ART and ART care between April 2012 and March 2013
in Lilongwe, Malawi.
Low-volume load facilities High-volume load facilities
0–12 months 0–24 months 0–12 months 0–24 months
Pre-ART
Total registered 226 226 1681 1681
Follow-up outcome
pre-ART follow-up 184 81% 158 70% 637 38% 351 21%
Started ART 39 17% 64 28% 253 15% 426 25%
LTFU¥ 0 0% 0 0% 791 47% 904 54%
Transferred out 2 <1% 3 <1% 0 0% 0 0%
Dead 1 <1% 1 <1% 0 0% 0 0%
ART
Total registered 1017 1017 8380 8380
ART outcomeβ
Alive and on ART 740 75% 675 69% 5097 61% 4174 50%
LTFU 207 21% 258 26% 2071 25% 2699 32%
Stopped ART 1 0% 1 <1% 7 <1% 12 <1%
Transferred out 8 1% 11 1% 1178 14% 1467 18%
Dead 21 2% 32 3% 18 <1% 19 <1%
High-volume load facilities enrolled at least 400 ART patients per year
¥LTFU: Loss to follow-up
β40 patients had no ART outcomes in paper-based facilities and 9 had no ART outcomes in EMR-based facilities
https://doi.org/10.1371/journal.pone.0188488.t002
Loss to follow-up in antiretroviral program
PLOS ONE | https://doi.org/10.1371/journal.pone.0188488 January 26, 2018 6 / 12
In the multivariable analysis of ART patients, the association between baseline age, BMI,
reason for starting ART, adherence to clinic appointments, ART re-initiation and patient vol-
ume facility and LTFU remained significant; the risk of LTFU among patients who were not
adherent to clinic appointments was more pronounced (Table 4). After adjusting for other fac-
tors, the associations between gender and location of the facility with LTFU were reversed;
being female, and receiving ART at a rural facility associated with an increased risk of LTFU.
Adherence to scheduled clinic appointments was poor if the reason for starting ART was preg-
nancy, breastfeeding, WHO stages 3 or 4 unlike in cases where treatment was started solely
based on a CD4 count of less than 350 cells/μl.
Discussion
This study describes LTFU from pre-ART and ART care at urban and rural HIV facilities with
low and high patient volumes. Overall LTFU was 48% and 26% per year in the pre-ART and
ART cohorts, respectively. Among the pre-ART and ART cohorts, being 35 years of age or
older and female were associated with reduced risk of LTFU. Advanced WHO clinical stage,
low BMI at ART initiation, poor adherence to clinic appointments and receiving HIV care in
rural facilities on the other hand were associated with increased risk of LTFU among ART
patients. Re-initiation of ART and receiving ART care at low-volume facilities on the other
hand were associated with decreased risk of LTFU.
Our findings highlight critical LTFU issues in pre-ART and ART cohorts. In the pre-ART
cohort, we observed an overall LTFU of 48% per year, which falls within the range of 23–88%
reported in a systematic review from SSA[11]. However, LTFU in our study was higher than
Table 3. Univariable and multivariable model of characteristics associated with loss to follow-up from pre-ART care in Lilongwe, Malawi.
Characteristics n Unadjusted RR (95% CI) P-value Adjusted RR (95% CI) P-value
Gender <0.001 <0.001
Female 1098 0.75 (0.66–0.86) 0.74 (0.64–0.87)
Male 809 1.00 1.00
Age <0.001 <0.001
15–24 361 1.11 (0.94–1.31) 1.13 (0.95–1.36)
25–34 865 1.00 1.00
35–44 457 0.79 (0.66–0.94) 0.72 (0.59–0.87)
45+ 220 0.77 (0.61–0.96) 0.73 (0.57–0.94)
BMI category 0.042 0.113
<18.5 157 1.26 (1.01–1.57) 1.20 (0.94–1.54)
18.5–24.9 1238 1.00 1.00
25.0+ 367 0.85 (0.72–1.01) 0.90 (0.75–1.09)
CD4 count at registration <0.001
<350 376 1.00
350–500 363 0.43 (0.35–0.54) - -
>500 354 0.56 (0.46–0.69) - -
WHO clinical stage 0.001 0.001
1 or 2 1352 1.00 1.00
3 222 1.35 (1.11–1.64) 1.31 (1.07–1.60)
4 61 1.68 (1.18–2.37) 1.60 (1.13–2.27)
RR: risk ratio; CI: confidence interval; adjusted models were based on available data only; CD4 was excluded in the multivariable analysis because data were available in
57% only
https://doi.org/10.1371/journal.pone.0188488.t003
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previously reported among pre-ART patients in Malawi possibly because of different defini-
tions of pre-ART patients[12][13]. Other studies used a limited definition of pre-ART patients
i.e. including only those in WHO stage 1 and 2 who were not eligible to start ART. In this
study, we defined pre-ART patients more broadly as all persons newly enrolled in HIV care
who had not started ART three months post-clinic registration, regardless of their clinical
stage or CD4 count. All low-volume facilities, using paper-based data management systems,
did not document LTFU status in pre-ART patient card, despite the national guidelines rec-
ommendation to document and report all persons who have missed their appointments by 60
days as LTFU. High-volume facilities, on the other hand, have an in-built EMR feature that
automatically assigns LTFU status while paper-based systems require that staff review and
Table 4. Univariable and multivariable model of characteristics associated with loss to follow-up from ART care in Lilongwe, Malawi.
Characteristics nΩ Unadjusted RR(95% CI) P-value Adjusted RR(95% CI) P-value
Gender <0.001 <0.001
Female 6190 1.27 (1.18–1.38) 0.84 (0.76–0.93)
Male 3139 1.00 1.00
Age <0.001 <0.001
15–24 1577 1.42 (1.29–1.55) 1.35 (1.21–1.49)
25–34 4173 1.00 1.00
35–44 2411 0.65 (0.59–0.72) 0.70 (0.63–0.78)
45 1122 0.67 (0.59–0.77) 0.75 (0.65–0.88)
BMI category <0.001 <0.001
<18.5 1354 1.22 (1.10–1.36) 1.24 (1.11–1.39)
18.5–24.9 5673 1.00 1.17
25.0 1,816 0.94 (0.85–1.03) 0.90 (0.82–1.00)
Reason for starting ART <0.001
CD4 below threshold 2692 1.00 1.00 <0.001
WHO 3 3140 1.46 (1.32–1.62) 1.34 (1.20–1.51)
WHO 4 826 1.98 (1.72–2.26) 1.87 (1.62–2.18)
Pregnant/breastfeeding 2447 2.51 (2.27–2.76) 1.77 (1.57–1.99)
Adherence to clinic appointment € <0.001 <0.001
Yes 4625 1.00 1.00
No 4723 2.71 (2.51–2.93) 4.55 (4.16–4.97)
ART re-initiation <0.001 <0.001
0 6287 1.00 1.00
1 1825 0.42 (0.38–0.47) 0.20 (0.17–0.22)
2 887 0.19 (0.15–0.23) 0.06 (0.05–0.07)
Facility location <0.025 <0.001
Rural 981 0.88 (0.78–0.99) 2.32 (1.94–2.77)
Urban 8367 1.00 1.00
Facility patient load <0.001 <0.001
Low-volume 977 0.65 (0.57–0.74) 0.25 (0.20–0.30)
High-volume 8371 1.00 1.00
ΩIncluded only patients with follow-up time; RR: risk ratio, CI: confidence interval
 High-volume load facilities enrolled at least 400 ART patients per year
€Compliance; at least 80% of visits happened before 7 days after the scheduled clinic appointment date; ART re-initiation; starting ART after failure to come to the clinic
for at least 60 days from the date the patient was expected to return to the clinic: Some patients had no data for age (46(<1%), reason for starting ART (224(2%)) and
ART reinitiation (349(4%)
https://doi.org/10.1371/journal.pone.0188488.t004
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update patient cards for patients who are LTFU. Documentation of some data elements was
suboptimal at low-volume facilities compared to high-volume facilities. For example, BMI and
WHO clinical stage were not documented for 40% and 45% of the pre-ART patients’ records
respectively versus 3% and 10% in high-volume facilities with EMR. In addition, the LTFU
rates were almost twice as high in the pre-ART cohort compared to ART cohort. This may be
because of less attention being given to towards interventions that reduce LTFU in pre-ART
prior to the test-and-treat era.
Since July 2016, Malawi implemented the test-and-treat approach for ART initiation[14].
Given referral challenges, special clinical considerations, personal preferences and care provid-
er’s recommendations, not all newly identified HIV positive individuals will initiate ART on
the same day of testing or within seven days as recommended by Malawi guidelines. HIV-
infected individuals that have not been initiated on ART on the same day of testing may need
to be prioritized by enhancing measures that encourage utilization of HIV care services and
active patient tracing to prevent high LTFU rates.
Among patients on ART, we observed LTFU of 26% per year, higher in high-volume facili-
ties (27%) compared to low-volume facilities (17%). We acknowledge that some of the ART
patients may have continued ART elsewhere without a formal transfer-out note, died or simply
stopped ART as previous research in Malawi showed [6]. However, the rate of LTFU was still
higher than previously reported in the Malawi national ART program where it was 9% per
year prior to the implementation of Option B+ [9]. Previous studies have shown high LTFU
among women who initiate ART while pregnant or breastfeeding [15–17]. A quarter of the
ART patients in this study started ART based on Option B+ criteria and contributed to 39% of
the all LTFU patients were LTFU from Option B+. We previously conducted a study where we
noted that 47% of pregnant women LTFU received ART only once from a health care provider
and missed subsequent appointments, indicating that they may never have started ARVs[16].
Same day ART initiation for pregnant and breastfeeding women may result in inadequate
patient preparation, missed opportunities for disclosure, and social support, all of which can
contribute to LTFU. Being asymptomatic may contribute to unwillingness to comply with
scheduled appointment dates among pregnant and breastfeeding women because they feel
healthy and do not perceive the need for medications to sustain their health. Comprehensive
interventions to reduce LTFU need to specifically target pregnant and breastfeeding women
who start ART for life.
We also observed that high-volume facilities reported higher LTFU rates compared to low-
volume facilities. One possible explanation for this may be that high patient-to-provider ratios
limit individualized patient education, patient preparation before ART initiation, and ongoing
counselling once individuals are on lifelong therapy. Models of HIV service delivery that
reduce congestion at health facilities including community-based ART distribution systems,
multi-month ART appointments, utilization of other cadres and/or task shifting for adherence
counseling, and providing larger quantities of ARVs per visit for stable patients. Similar to pre-
vious studies of pre-ART cohorts, we found that being female, older than 35 years, and having
a high CD4 count were associated with a lower risk of LTFU [11][18]. On the other hand, low
BMI and the presence of WHO stages 3 or 4 defining illnesses at enrollment was associated
with a high risk of LTFU. Some of the patients with WHO stages 3 or 4 may have experienced
unreported deaths [18]. In cases where CD4 criteria was used for ART eligibility, low CD4
were found to be at risk for LTFU most likely for reason similar to those with WHO stages 3
or 4.
Among those who started ART, patients were less likely to be LTFU again if they returned
to care and re-initiated ART. The decreased LTFU after re-initiation of care may also be attrib-
uted to the stable lifestyles of individuals in regards to living with HIV and being in care, to the
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counseling they received upon return to care, or the experience of negative outcomes such as
opportunistic infections and weight loss encountered when care was interrupted. We also
noted a high risk of LTFU among younger patients, women, those in urban setting, and those
who received care at high-volume facilities. In the multivariable analysis, being female was
associated with a lower risk of LTFU after adjusting for confounding factors such as age, rea-
son for starting treatment and compliance to scheduled appointment dates. Younger women,
those who started ART due to pregnancy or breastfeeding, and those who had never been
reinitiated on treatment were more likely to be LTFU, while those reinitiated on treatment at
least once were less likely to be LTFU. These factors may be contributors to LTFU in countries
that have adopted a universal Test and Treat strategy for pregnant and breastfeeding women.
HIV programs that use Option B and B+ strategies will need to employ specific interventions,
such as active tracing of patients that miss their appointments, prioritization of pregnant and
breastfeeding women to optimize retention to care. On the other hand, receiving care from
low-volume facilities where patient-to-provider ratios may be lower and may allow for more
patient-centered care was associated with lower risk of LTFU–thereby contributing to better
adherence to scheduled clinic appointments. An additional factor that negatively impacted
adherence to clinic visits was receiving care in a rural facility. ART reinitiating also negatively
influenced the risk for LTFU among people receiving ART in a rural facility. Non-adherence
to clinic visits has been reported to be independently associated with all-cause mortality [19].
In Malawi, some high-volume facilities are piloting Demographic Data Exchange (DDE)
systems that generate a unique national identification (ID). The ID enable tracking of unique
HIV positive individuals at different points across the HIV care continuum. Such approaches
facilitate tracking of ART patients who transfer care without a formal clinical documentation.
The DDE technology can be utilized to identify patients who access ARVs at another facility
and determine patients who transfer or receive ad-hoc care without a formal documentation.
Expanding such systems however will also need to consider how such technology can be mir-
rored in facilities that use paper-based records. Additionally, such systems will need to be
implemented in parallel with the development and implementations of privacy laws and guide-
lines on protecting the confidentiality and security of personal health information.
Our study is subject to some limitations that should be taken into account when interpret-
ing the findings. First, some patients might have been classified as LTFU simply because their
true status was not known by the facility where they first sought care. We cannot therefore rule
out the possibility that some patients transferred their care elsewhere or may have died. Sec-
ond, we may have underestimated the true incidence of LTFU due to the incomplete docu-
mentation at paper-based facilities. Third, it is possible that some of the patients classified as
LTFU may have died resulting in an overestimation of LTFU. Fourth, pre-ART and ART data
were not available for some patients in paper-based facilities. Since the models were based on
variables with variable data, this might have led to selection bias in our estimates. Lastly, we
could not explore the effect of patient volume and location of the facility on pre-ART LTFU
because of the small numbers of LTFU patients. Despite these limitations, our study findings
shed light on additional factors related to LTFU such as adherence to clinic appointment,
patient volume, re-initiation of ART and the effect of Option B+ on the overall ART cohort.
In summary, higher rates of LTFU were observed in pre-ART care when compared with
ART care. Women who started ART because of Option B+ contributed significantly to LTFU.
Non-adherence to clinic appointments, and receiving HIV care in a high-volume facility or
rural facility were associated with increased risk of LTFU. Data incompleteness within paper-
based data systems.is a challenge that calls for standardized operating systems or EMRs that
monitor and easily flag LTFU patients in pre-ART and ART care; this may promote actions
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that reduce LTFU. Interventions that target high risk sub-groups and contexts may also pre-
vent LTFU.
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